These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 10647667

  • 1. The perioperative charge equivalence of interstitial brachytherapy and radical prostatectomy with 1-year followup.
    Kohan AD, Armenakas NA, Fracchia JA.
    J Urol; 2000 Feb; 163(2):511-4. PubMed ID: 10647667
    [Abstract] [Full Text] [Related]

  • 2. Charge and length of hospital stay analysis of radical retropubic prostatectomy and transperineal prostate brachytherapy.
    Wagner TT, Young D, Bahnson RR.
    J Urol; 1999 Apr; 161(4):1216-8. PubMed ID: 10081872
    [Abstract] [Full Text] [Related]

  • 3. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis.
    Polascik TJ, Pound CR, DeWeese TL, Walsh PC.
    Urology; 1998 Jun; 51(6):884-9; discussion 889-90. PubMed ID: 9609622
    [Abstract] [Full Text] [Related]

  • 4. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma.
    Brandeis J, Pashos CL, Henning JM, Litwin MS.
    Cancer; 2000 Oct 15; 89(8):1792-9. PubMed ID: 11042575
    [Abstract] [Full Text] [Related]

  • 5. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
    Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R.
    Brachytherapy; 2005 Oct 15; 4(1):34-44. PubMed ID: 15737905
    [Abstract] [Full Text] [Related]

  • 6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Oct 15; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 7. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005.
    Colberg JW, Decker RH, Khan AM, McKeon A, Wilson LD, Peschel RE.
    Cancer J; 2007 Oct 15; 13(4):229-32. PubMed ID: 17762756
    [Abstract] [Full Text] [Related]

  • 8. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H.
    J Urol; 2000 Jul 15; 164(1):101-5. PubMed ID: 10840432
    [Abstract] [Full Text] [Related]

  • 9. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR, McNeal JE, Gill H, Presti JC.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):386-91. PubMed ID: 15145152
    [Abstract] [Full Text] [Related]

  • 10. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS.
    J Urol; 2004 Mar 01; 171(3):1098-104. PubMed ID: 14767279
    [Abstract] [Full Text] [Related]

  • 11. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb 01; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 12. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug 01; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 13. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Guzzo TJ, Levin BM, Lee R, Guo M, Chen Z, Whittington R, Tomaszewski J, Malkowicz SB.
    Urology; 2008 Apr 01; 71(4):723-7. PubMed ID: 18387401
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcomes in younger men following permanent prostate brachytherapy.
    Shapiro EY, Rais-Bahrami S, Morgenstern C, Napolitano B, Richstone L, Potters L.
    J Urol; 2009 Apr 01; 181(4):1665-71; discussion 1671. PubMed ID: 19233394
    [Abstract] [Full Text] [Related]

  • 15. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
    Ragde H, Grado GL, Nadir BS.
    Arch Esp Urol; 2001 Sep 01; 54(7):739-47. PubMed ID: 11692443
    [Abstract] [Full Text] [Related]

  • 16. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA.
    J Urol; 2007 Jun 01; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [Abstract] [Full Text] [Related]

  • 17. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA.
    Urology; 2004 Mar 01; 63(3):528-31. PubMed ID: 15028451
    [Abstract] [Full Text] [Related]

  • 18. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA, Shappell SB.
    J Urol; 2002 Aug 01; 168(2):519-24. PubMed ID: 12131301
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS, Bianco FJ, Scardino PT, Eastham JA.
    J Urol; 2006 Aug 01; 176(2):564-8. PubMed ID: 16813890
    [Abstract] [Full Text] [Related]

  • 20. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
    Borchers H, Kirschner-Hermanns R, Brehmer B, Tietze L, Reineke T, Pinkawa M, Eble MJ, Jakse G.
    BJU Int; 2004 Oct 01; 94(6):805-11. PubMed ID: 15476513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.